Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice - PubMed (original) (raw)
. 2007 May 1;109(9):1777-83.
doi: 10.1002/cncr.22615.
Affiliations
- PMID: 17354226
- DOI: 10.1002/cncr.22615
Free article
Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice
Mark S Litwin et al. Cancer. 2007.
Free article
Abstract
Background: Among the most pressing challenges that face physicians who care for men with prostate cancer is evaluating the patient's potential for benefiting from treatment. Because prostate cancer often follows an indolent course, the presence and severity of comorbidities may influence the decision to treat the patient aggressively. The authors adapted the Total Illness Burden Index (TIBI) for use in decision-making among men with prostate cancer at the time of the visit.
Methods: An observational study was performed of 2894 participants in the Cancer of the Prostate Strategic Urologic Research Endeavor, a national disease registry of men with prostate cancer, to examine how well the adapted TIBI for prostate cancer (TIBI-CaP) predicted mortality over the subsequent 3.5 years and health-related quality of life over the subsequent 6 months.
Results: The men who had the highest global TIBI-CaP scores were 13 times more likely to die of causes other than prostate cancer over a 3.5-year period than the men who had the lowest scores (hazard ratio, 13.1, 95% confidence interval, 6.3-27.4) after controlling for age, education, income, and race/ethnicity. Patients who had the highest TIBI-CaP scores had 44% mortality compared with 4.9% mortality for patients who had the lowest scores. Demographic variables explained 16% of the variance in future physical function; TIBI-CaP scores explained an additional 19% of the variance.
Conclusions: The TIBI-CaP, a patient-reported measure of comorbidity, identified patients at high risk for nonprostate cancer mortality. It predicted both mortality and future quality of life. The TIBI-CaP may aid physicians and patients in making appropriate treatment decisions.
Copyright (c) 2007 American Cancer Society
Similar articles
- From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer.
Daskivich TJ, van de Poll-Franse LV, Kwan L, Sadetsky N, Stein DM, Litwin MS. Daskivich TJ, et al. Prostate Cancer Prostatic Dis. 2010 Dec;13(4):320-7. doi: 10.1038/pcan.2010.33. Epub 2010 Sep 14. Prostate Cancer Prostatic Dis. 2010. PMID: 20838413 - Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N, Lubeck DP, Pasta DJ, Latini DM, DuChane J, Carroll PR. Sadetsky N, et al. BJU Int. 2008 Mar;101(6):691-7. doi: 10.1111/j.1464-410X.2007.07353.x. BJU Int. 2008. PMID: 18291018 - Who is the average patient presenting with prostate cancer?
Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR; Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators. Greene KL, et al. Urology. 2005 Nov;66(5 Suppl):76-82. doi: 10.1016/j.urology.2005.06.082. Urology. 2005. PMID: 16194711 - The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR; CaPSURE Investigators. Cooperberg MR, et al. J Urol. 2004 Apr;171(4):1393-401. doi: 10.1097/01.ju.0000107247.81471.06. J Urol. 2004. PMID: 15017184 Review. - On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer.
Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF. Ramsey SD, et al. J Urol. 2007 Jun;177(6):1992-9. doi: 10.1016/j.juro.2007.01.138. J Urol. 2007. PMID: 17509278 Review.
Cited by
- Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer.
Hoffman RM, Koyama T, Fan KH, Albertsen PC, Barry MJ, Goodman M, Hamilton AS, Potosky AL, Stanford JL, Stroup AM, Penson DF. Hoffman RM, et al. J Natl Cancer Inst. 2013 May 15;105(10):711-8. doi: 10.1093/jnci/djt059. Epub 2013 Apr 24. J Natl Cancer Inst. 2013. PMID: 23615689 Free PMC article. - Functional Outcomes After Localized Prostate Cancer Treatment.
Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, O'Neil BB, Koyama T, Hoffman KE, Barocas DA. Al Hussein Al Awamlh B, et al. JAMA. 2024 Jan 23;331(4):302-317. doi: 10.1001/jama.2023.26491. JAMA. 2024. PMID: 38261043 Free PMC article. - Low-risk prostate cancer and low testosterone: what are the acceptable alternatives?
Soloway M. Soloway M. Curr Urol Rep. 2009 Nov;10(6):413-7. doi: 10.1007/s11934-009-0078-8. Curr Urol Rep. 2009. PMID: 19863851 No abstract available. - Do rapid emotional thermometers correlate with multidimensional validated structured questionnaires in low-risk prostate cancer?
Laranja WW, Pereira TA, Guimarães PVB, Tobias-Machado M, Leandro-Merhi VA, de Aquino JLB, Reis LO. Laranja WW, et al. Int Urol Nephrol. 2020 Jun;52(6):1073-1078. doi: 10.1007/s11255-020-02399-w. Epub 2020 Feb 13. Int Urol Nephrol. 2020. PMID: 32056135 - Patient complexity and risk factor control among multimorbid patients with type 2 diabetes: results from the R2D2C2 study.
Malik S, Billimek J, Greenfield S, Sorkin DH, Ngo-Metzger Q, Kaplan SH. Malik S, et al. Med Care. 2013 Feb;51(2):180-5. doi: 10.1097/MLR.0b013e318273119b. Med Care. 2013. PMID: 23047130 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous